Prostate Cancer - Results from #160

Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis. November 20, 2024

Small-molecule disruption of androgen receptor-dependent chromatin clusters. November 20, 2024

A Systematic Review of the Diagnostic Accuracy of Deep Learning Models for the Automatic Detection, Localization, and Characterization of Clinically Significant Prostate Cancer on Magnetic Resonance Imaging. November 20, 2024

Colibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer. November 20, 2024

Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. November 20, 2024

Comparison of online adaptive and non-adaptive magnetic resonance image-guided radiation therapy in prostate cancer using dose accumulation. November 19, 2024

Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer. November 19, 2024

[225Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. November 19, 2024

Association between beta-blocker atenolol use and prostate cancer upgrading in active surveillance. November 19, 2024

Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer. November 19, 2024

The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer. November 19, 2024

St Vincent’s Hospital to Conduct Head-to-Head Trial with Clarity’s SAR-bisPSMA Diagnostic Product November 18, 2024

Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers. November 18, 2024

HSD3B1, prostate cancer mortality and modifiable outcomes. November 18, 2024

Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries. November 18, 2024

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings. November 18, 2024

Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials. November 18, 2024

Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer. November 18, 2024

Striving for Equity: Examining Health Disparities in Urologic Oncology. November 18, 2024

Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review. November 15, 2024

Page 9 of 1447